Jefferies Downgrades Fusion Pharmaceuticals (FUSN) to Hold

Morgan Stanley Downgrades Fusion Pharmaceuticals (FUSN) to Equalweight

Morgan Stanley analyst Matthew Harrison downgraded Fusion Pharmaceuticals (NASDAQ: FUSN) from Overweight to Equalweight with a price target of $21.00 (from $10.00).

The analyst comments "Fusion to be acquired by AstraZeneca for $21/share in cash payable at deal closing (vs. 03/18 closing price of $10.64),... More

Wedbush Downgrades Fusion Pharmaceuticals (FUSN) to Neutral

Wedbush analyst David Nierengarten downgraded Fusion Pharmaceuticals (NASDAQ: FUSN) from Outperform to Neutral with a price target of $24.00.

For an analyst ratings summary and ratings history on Fusion Pharmaceuticals click here. For more ratings news on Fusion Pharmaceuticals click here.

Shares of Fusion Pharmaceuticals closed at $10.64 yesterday.

Midday movers: Nvidia, Coinbase fall; Unilever rises

(Updated - March 19, 2024 11:20 AM EDT)

Investing.com -- Main U.S. indexes slipped lower Tuesday, amid caution ahead of the start of an eagerly-awaited Federal Reserve policy-setting meeting.

Here are some of the biggest U.S. stock movers today:

Nvidia (NASDAQ: NVDA) stock fell 2% as the chipmaker gave back some of the impressive gains seen this year after it unveiled its new line of AI chips at its annual developer conference. Shares AMD (NASDAQ:... More

Leerink Partners Downgrades Fusion Pharmaceuticals (FUSN) to Market Perform

Leerink Partners analyst Faisal Khurshid downgraded Fusion Pharmaceuticals (NASDAQ: FUSN) from Outperform to Market Perform with a price target of $21.00 (from $17.00).

For an analyst ratings summary and ratings history on Fusion Pharmaceuticals click here. For more ratings news on Fusion Pharmaceuticals click here.

Shares of Fusion Pharmaceuticals closed at $10.64 yesterday.

Fusion Pharmaceuticals (FUSN) Acquired by AstraZeneca (AZN) for $21/sh Cash + $3 CVR

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines, today announced the Company has entered into a definitive agreement to be acquired by AstraZeneca (NASDAQ: AZN). The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments.

RCs have emerged as a promising modality in cancer treatment over recent years.... More